Dashboard
Manage Tickers

NUVL


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

why-nuvalent-nuvl-shares-are-down-6-today
Why Nuvalent (NUVL) Shares Are Down 6% Today
09/17/2024 18:37:17

Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 ...

reported-earlier-nuvalent-prices-500m-upsized-public-offering-of-5m-common-share-at-100share
Reported Earlier, Nuvalent Prices $500M Up...
09/17/2024 06:42:35

nuvalent-stock-jumps-on-esmo-data-presentation-seeks-to-raise-350m-via-equity
Nuvalent Stock Jumps On ESMO Data Presenta...
09/16/2024 17:44:01

Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promisi...

guggenheim-maintains-buy-on-nuvalent-raises-price-target-to-105
Guggenheim Maintains Buy on Nuvalent, Rais...
09/16/2024 16:43:48

Guggenheim analyst Kelsey Goodwin maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $99 to $105.

wedbush-maintains-outperform-on-nuvalent-raises-price-target-to-115
Wedbush Maintains Outperform on Nuvalent, ...
09/16/2024 16:36:24

Wedbush analyst David Nierengarten maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $99 t...

crude-oil-surges-over-1-instil-bio-shares-plunge
Crude Oil Surges Over 1%; Instil Bio Share...
09/16/2024 16:31:33

alcoa-lattice-semiconductor-stratasys-and-other-big-stocks-moving-higher-on-monday
Alcoa, Lattice Semiconductor, Stratasys An...
09/16/2024 14:03:58

bmo-capital-maintains-outperform-on-nuvalent-raises-price-target-to-132
BMO Capital Maintains Outperform on Nuvale...
09/16/2024 12:54:08

BMO Capital analyst Etzer Darout maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $102 to...

stifel-maintains-buy-on-nuvalent-raises-price-target-to-135
Stifel Maintains Buy on Nuvalent, Raises P...
09/16/2024 12:02:13

Stifel analyst Bradley Canino maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $115 to $135.

nuvalent-has-commenced-an-underwritten-public-offering-of-350m-other-deal-terms-undisclosed
Nuvalent Has Commenced An Underwritten Pub...
09/16/2024 11:02:29

reported-saturday-nuvalent-highlights-results-for-ros1-and-alk-positive-nsclc-programs-accelerates-development-timeline
Reported Saturday, Nuvalent Highlights Res...
09/16/2024 08:32:35

Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class pr...

nuvalent-publishes-cancer-discovery-detailing-design-and-characterization-of-alk-selective-inhibitor-nvl-655
Nuvalent Publishes Cancer Discovery Detail...
09/13/2024 14:00:09

Publication provides comprehensive assessment of NVL-655's preclinical activity and includes preliminary clinical case studies

nuvalent-announced-cancer-discovery-publication-highlighting-design-preclinical-activity-and-early-clinical-data-of-alk-selective-inhibitor-nvl-655
Nuvalent Announced Cancer Discovery Public...
09/13/2024 13:56:30

- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for...

wedbush-reiterates-outperform-on-nuvalent-maintains-99-price-target
Wedbush Reiterates Outperform on Nuvalent,...
09/09/2024 12:37:59

Wedbush analyst David Nierengarten reiterates Nuvalent (NASDAQ:NUVL) with a Outperform and maintains $99 price target.

nuvalent-to-present-cancer-therapy-data-at-esmo-2024-highlighting-key-trials
Nuvalent to Present Cancer Therapy Data at...
09/09/2024 10:31:59

 Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for ...

jp-morgan-maintains-overweight-on-nuvalent-raises-price-target-to-100
JP Morgan Maintains Overweight on Nuvalent...
09/04/2024 22:14:29

JP Morgan analyst Anupam Rama maintains Nuvalent (NASDAQ:NUVL) with a Overweight and raises the price target from $90 to $100.

barclays-initiates-coverage-on-nuvalent-with-overweight-rating-announces-price-target-of-100
Barclays Initiates Coverage On Nuvalent wi...
08/29/2024 12:49:36

Barclays analyst Carter Gould initiates coverage on Nuvalent (NASDAQ:NUVL) with a Overweight rating and announces Price Targ...

lucid-grifols-and-amer-sports-are-among-top-8-mid-cap-stock-gainers-last-week-aug-18-aug-24-are-the-others-in-your-portfolio
Lucid, Grifols And Amer Sports Are Among T...
08/25/2024 20:45:28

nuvalent-cash-cash-equivalents-and-marketable-securities-of-658m-is-expected-to-support-operating-runway-into-2027
Nuvalent Cash, Cash Equivalents And Market...
08/08/2024 10:39:07

nuvalent-q2-2024-gaap-eps-088-misses-076-estimate
Nuvalent Q2 2024 GAAP EPS $(0.88) Misses $...
08/08/2024 10:38:04

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION